Arcus Biosciences - RCUS Net Assets per Single Share

Graphic logo of Arcus Biosciences (RCUS)

The visual price representation available on the page serves as an indicator for Arcus Biosciences, Inc. (RCUS), whose operations rely on strict biomaterial logistics management through a network of laboratories to protect margins. Internal testing cycles and partnerships with pharma behemoths determine the share price at 3.67, neutralizing macroeconomic influence. Meanwhile, Arcus Biosciences, Inc. (RCUS) outsources manufacturing and clinical trials to third-party contractors, focusing on the development of new therapies.

RCUS: Arcus Bio Net Asset Value per Share 07/04/2022 - 10/28/2026

arcusbio.com - analytical breakdowns and key metrics (RCUS)

- price and consensus price forecast:
Stock Quotes Arcus Bio|RCUS - Analyst Consensus Forecast
- market capitalization data:
Market Value Arcus Biosciences, Inc.|RCUS - Company Buyout Price
- book capitalization data:
Net Assets per Single Share Arcus Biosciences|RCUS - Total Stockholders' Equity|Market Value to Book Value Ratio arcusbio.com|RCUS - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Arcus Biosciences, Inc.|RCUS - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Arcus Biosciences|RCUS - Company Cumulative Debt|Debt to Book Capitalization Ratio Arcus Biosciences, Inc.|RCUS - Company Long-Term Debt|Company Short-Term Debt Arcus Biosciences
Fundamental company valuation:RCUS - Arcus Bio
Flagship merchandise of Arcus Biosciences

For the biotechnology sector, Arcus Biosciences, Inc. (RCUS) utilizes book value per share as an indicator of internal capital stability. This metric is calculated as the difference between total assets and liabilities, divided by the number of shares outstanding. By analyzing changes in BVPS, an investor assesses the real value of net assets. For Arcus Biosciences, Inc. (RCUS), this figure reflects the financing efficiency provided by Gilead Sciences. Growth in value confirms the company's investment attractiveness as an acquisition target.

Competitor analysis for Arcus Biosciences, Inc.

ImmunityBio Corp - Accounting Value per Share|IMCR: Book Value per Share|Janux Therapeutics - Net Assets per Single Share|ZYME (zymeworks.com) - Net Assets per Share|Net Assets per Single Share TNGX (Tango Therapeutics, Inc.)|Net Asset Value per Share IOVA|Net Assets per Single Share Immatics Corp IMTX|Equity per Share Xencor Inc. (XNCR)|Compass Therapeutics - Book Value per Share|replimune.com - Accounting Value per Share|LYEL (Lyell Immunopharma, Inc.) - Net Assets per Single Share|IPHA: Net Asset Value per Share|pyxisoncology.com (PYXS) - Net Assets per Single Share|CGEN (Compugen) - Net Assets per Single Share|Net Assets per Single Share IOBT (IO Biotech, Inc.)|Net Asset Value per Share sutrobio.com|INKT: Book Value per Share|Book Value of One Share werewolftx.com HOWL|IMMX: Accounting Value per Share|ALXO - Net Asset Value per Share|Accounting Value per Share Cue Biopharma, Inc. (CUE)|PDSB - Accounting Value of a Share|sonnetbio.com - Book Value per Share|MAIA (MAIA Biotech) - Net Assets per Share|Net Assets per Single Share LIMN|Accounting Value per Share LVTX|Net Assets per Single Share NXTC (NextCure, Inc.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx